**StATS: **Number Needed to Treat (created 2000-01-27).

*Dear Professor Mean, How are patients and
their doctors supposed to decide whether a research finding has practical
significance? Why don't the medical journals make things clearer?*

You're hoping for clarity from medical profession? These are the folks who take a simple ear ache and call it "otitis media." To them, a runny nose is "rhinorhea" and a tummy ache is "gastrointestinal distress." It's enough to make me produce lacrimal secretions.

In fairness to these folks, though, they do realize that practical interpretation of the medical research is difficult. They are trying to change it. There are two important changes that we are starting to see in medical research papers. First, they have learned that

you can't ignore the size of the effect and focus only on the statistical significance. Since confidence intervals provide information about both the size and significance, many journals include them instead of p-values.

A second change is the realization that

absolute changes in risk are more important than relative changes in risk. A nurse recently informed me that my snoring (oops! sleep apnea) can triple the risk of a stroke (excuse me, a cerebrovascular event) if left untreated. But how serious is that for someone who is only 42 years old and otherwise in good health? Three times nothing is nothing, and three times something very small is still very small. I decided to get treatment, but it was more for helping me and my wife to sleep better than a concern about stroke.

A good measure of the absolute risk is the

number needed to treat (NNT). It is the average number of patients that a doctor would need to treat in order to have one additional event occur. A small value (e.g., NNT=2.7) means that a doctor will see a lot of events in very little time. A large value (e.g., NNT=800) means that the doctor will have to treat a large number of patients in order to see a very few events.When you are measuring

an increase in bad events like side effects that might be associated with a treatment, then the number needed to treat is sometimes described as thenumber needed to harm (NNH). Often you can quantify the tradeoffs between the benefits and side effects of a treatment by comparing the NNT and NNH values.

**Some examples**

Here are some examples of Numbers Needed to Treat, found at the Bandolier web site (http://www.jr2.ox.ac.uk/bandolier/index.html).

Prevention of post-operative vomiting using Droperidol, NNT=4.4. For every four or five surgery patients treated with Droperidol, you will see one less vomiting incident on average.

Prevention of infection from dog bites using antibiotics, NNT=16. For every 16 dog bites treated with antibiotics, you would see one fewer infection on average.

Primary prevention of stroke using a daily low dose of aspirin for one year, NNT=102. For every hundred patient years of treatment with aspirin, you will see one fewer stroke on average.Notice that this

last event is a rate. Assuming that the rates are reasonably homogenous over time,one hundred patient yearsis equivalent tofollowing ten patients for a decade. Be careful, of course, of rates that are not homogenous over time. If the rates decline the longer you follow your patients, then the number of events you will see for one hundred patients during their first year of therapy would be quite different from the number of events you would see following ten patients for their first decade of therapy.Here's another example from the British Medical Journal (Freemantle 1999: 318(7200); 1730-1737).

Prevention of cardiac death using beta blockers among patients with previous myocardial infarction, NNT=42.For every 42 patients treated for two years with beta blockers, you would see one fewer death. This is superior totreatment with antiplatelet agents (NNT=153), Statins (NNT=94), or Warfarin (NNT=63), but not as effective asthrombolysis and aspirin for 4 weeks (NNT=24).

**Computational Example**

To compute the NNT, you need to

subtract the rate in the treatment group from the rate in the control group and then invert it(divide the difference into 1).A recently published article on the flu vaccine showed that

among the children who received a placebo, 17.9% later had culture confirmed influenza. In thevaccine group, the rate was only 1.3%. This is a16.6% absolute difference. When you invert this percentage, you getNNT=6. This means thatfor every six kids who get the vaccine, you will see one less case of flu on average.The study also looked at the rate of side effects. In the

vaccine group, 1.9% developed a fever. Only0.8% of the controls developed a fever. This is an absolute difference of 1.1%. When you invert this percentage, you getNNH=90. This means thatfor every 90 kids who get the vaccine, you will see one additional fever on average.Sometimes the

ratio between NNT and NNHcan prove informative. For this study,NNH/NNT=90/6=15. This tells you that you shouldexpect to see one additional fever for every fifteen cases of flu prevented.Although I am not a medical expert, the vaccine looks very promising because

you can prevent a lot of flu events and only have to put up with a few additional fevers. In general, it takes medical judgment to assess the trade-offs between the benefits of a treatment and its side effects. The NNT and NNH calculations allow you to assess there trade-offs.

**What if the outcome measure is continuous?**

To calculate the NNT or NNH, you need to have a

distinct event. With a continuous variable, you could define such an event bysetting a cut-off. For example, an intervention to improve breastfeeding rates might improve theaverage duration of breastfeeding by seven weeks. How would you calculate the NNT for this data? Well, you might declare that you are interested in the proportion of mothers who breastfeed for at least 12 weeks. If you had access to the original data, you would find that54% of women in the control group and 87% in the treatment group breastfed for at least 12 weeks. This would allow you to compute anNNT of 3. For every three mothers given the new intervention, one additional mother would breastfeed beyond 12 weeks.The choice of 12 weeks is somewhat arbitrary and

you would get different results if you chose a different cut-off, such as 24 weeks. You shouldchoose a value that has clinical relevanceto your colleagues.Calculating the NNT or NNH from a continuous measure using a cutoff is usually impossible to do after the fact.

So if you are reading someone else's work and they present the data as a mean difference, you cannot calculate NNT or NNH.You would need additional information, such as the proportions that exceed some threshold, or you would have to make some questionable assumptions, such as normality for the outcome measure.

**Summary**

Professor Mean explains that the journals are getting better at presenting the practical implications of the research. In particular, they are presenting the number needed to treat, a measure that helps you better understand the practical significance of your research findings.

The number needed to treat is the average number of patients that you will have to treat with a new therapy to see one additional success, on average, compared to the standard therapy.

**Further Reading**

**2-way Contingency Table Analysis**. John C. Pezzullo. Accessed on 2003-08-11. members.aol.com/johnp71/ctab2x2.html**Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms.**R Riegelman, WS Schroth. Medical Decision Making 1993: 13(3); 247-52. [Medline]**Applying evidence to the individual patient.**S. E. Straus, D. L. Sackett. Ann Oncol 1999: 10(1); 29-32. [Medline]**Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association [published erratum appears in Can Med Assoc J 1995 Mar 15; 152(6):813].**R. Jaeschke, G. Guyatt, H. Shannon, S. Walter, D. Cook, N. Heddle. Cmaj 1995: 152(3); 351-7. [Medline] [Full text]**Benefit-Risk ratios in the assessment of the clinical evidence of a new therapy.**AR Willan, BJ O'Brien, DJ Cook. Cont Clin Trials 1997: 18(2); 121-30. [Medline]**Beta blockade after myocardial infarction: systematic review and meta regression analysis.**Nick Freemantle, J Cleland, P Young, J Mason, J Harrison. British Medical Journal 1999: 318(7200); 1730-1737. [Medline] [Abstract] [Full text] [PDF]**Calculating and Using NNTs**. Bandolier. Accessed on 2003-06-12. www.jr2.ox.ac.uk/bandolier/Extraforbando/NNTextra.pdf**Calculating confidence intervals for the number needed to treat.**R. Bender. Controlled Clinical Trials 2001: 22(2); 102-10. [Medline]**Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies.**R Bender, M Blettner. Journal of Clinical Epidemiology 2002: 55(5); 525-530. [Medline] [PDF]**Calculating the number needed to treat for trials where the outcome is time to an event.**D. G. Altman, P. K. Andersen. British Medical Journal 1999: 319(7223); 1492-5. [Medline] [Full text] [PDF]**Choice of Effect Measure for Epidemiological Data.**SD Walter. Journal of Clinical Epidemiology 2000: 53(9); 931-939. [Medline]**Confidence limits made easy: interval estimation using a substitution method.**L. E. Daly. Am J Epidemiol 1998: 147(8); 783-90. [Medline]**Events per person per year -- a dubious concept.**J Windeler, S Lange. BMJ 1995: 310(6977); 454-56. [Medline] [Full text]**Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed".**L. M. Bjerre, J. LeLorier. British Medical Journal 2000: 320(7233); 503-6. [Medline] [Full text] [PDF]**Getting NNTs**. Bandolier. Accessed on 2003-07-01. www.jr2.ox.ac.uk/bandolier/band36/b36-2.html**Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration.**H. C. Bucher, M. Weinbacher, K. Gyr. British Medical Journal 1994: 309(6957); 761-4. [Medline] [Abstract] [Full text]**Interpreting the Number Needed to Treat.**Lambert A. Wu, Thomas E. Kottke. Journal of the American Medical Association 2002: 288(7); 830-1. [Medline]**Missing the point (estimate)? Confidence intervals for the number needed to treat.**N. J. Barrowman. Cmaj 2002: 166(13); 1676-7. [Medline] [Full text] [PDF]**Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up.**T. Blondal, L. J. Gudmundsson, I. Olafsdottir, G. Gustavsson, A. Westin. British Medical Journal 1999: 318(7179); 285-8. [Medline] [Abstract] [Full text] [PDF]**Number needed to harm should be measured for treatments.**Arnold Zermansky. British Medical Journal 1998: 317(7164); 1014. [Medline] [Full text]**Number needed to screen: development of a statistic for disease screening.**C. M. Rembold. British Medical Journal 1998: 317(7154); 307-12. [Medline] [Abstract] [Full text] [PDF]**The number needed to treat: a clinically useful measure of treatment effect.**R. J. Cook, D. L. Sackett. British Medical Journal 1995: 310(6977); 452-4. [Medline] [Full text]**Number needed to treat: Caveat emptor.**LA Wu, TE Kottke. Journal of Clinical Epidemiology 2001: 54(2); 111-116. [Medline]**Numbers needed to treat derived from meta-analysis.**Bruce G. Charlton. British Medical Journal 1999: 319(7218); 1199. [Medline] [Full text]**Randomised controlled trial shows that glyceryl trinitrate heals anal fissures, higher doses are not more effective, and there is a high recurrence rate.**EA Carapeti, MA Kamm, PJ McDonald, SJ Chadwick, D Melville, RK Phillips. Gut 1999: 44(5); 727-30. [Medline] [Abstract]**Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta-analysis.**B. Ola, S. Papaioannou, M. A. Afnan, N. Hammadieh, S. Gimba. Fertil Steril 2001: 75(6); 1106-10. [Medline]**Unqualified success and unmitigated failure: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events.**M Schulzer, GB Mancini. International Journal of Epidemiology 1996: 25(4); 704-12. [Medline]**Updated New Zealand cardiovascular disease risk-benefit prediction guide.**R. Jackson. Bmj 2000: 320(7236); 709-10. [Medline] [Full text] [PDF]**Using numerical results from systematic reviews in clinical practice.**H. J. McQuay, R. A. Moore. Ann Intern Med 1997: 126(9); 712-20. [Medline]**When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.**J. C. Sinclair, R. J. Cook, G. H. Guyatt, S. G. Pauker, D. J. Cook. J Clin Epidemiol 2001: 54(3); 253-62. [Medline]

**Additional references that I need to add to my bibliography**

- BMJ 1999;318:1548-1551 ( 5 June ) http://bmj.bmjjournals.com/cgi/content/full/318/7197/1548
- J Clin Epidemiol. 2002 Jan;55(1):102-3. PMID: 11781128.
- JAMA. 2002 Jun 5;287(21):2813-4. PMID: 12038920

This page was written by Steve Simon while working at Children's Mercy Hospital. Although I do not hold the copyright for this material, I am reproducing it here as a service, as it is no longer available on the Children's Mercy Hospital website. Need more information? I have a page with general help resources. You can also browse for pages similar to this one at Category: Measuring benefit and risk